Hydrochlorothiazid-13C,d2

Hydrochlorothiazid-13C,d2

• CAS Number: 1190006-03-1
• UNSPSC Description: Hydrochlorothiazid-13C,d2 is the 13C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect[1][2][3].
• Target Antigen: Isotope-Labeled Compounds; Potassium Channel; TGF-beta/Smad
• Type: Isotope-Labeled Compounds
• Related Pathways: Membrane Transporter/Ion Channel;Others;Stem Cell/Wnt;TGF-beta/Smad
• Applications: Metabolism-protein/nucleotide metabolism
• Field of Research: Metabolic Disease; Cardiovascular Disease
• Purity: 98.64
• Solubility: 10 mM in DMSO
• Smiles: O=S1(C2=CC(S(N)(=O)=O)=C(Cl)C=C2N[13C]([2H])([2H])N1)=O
• Molecular Weight: 300.74
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.|[2]Duarte, J.D. and R.M. Cooper-DeHoff, Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther, 2010. 8(6): p. 793-802.|[3]Jinghong Luo, et al. Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats. Cardiovasc Ther. 2017 Apr;35(2).|[4]Magdy M Abdelquader, et al. Inhibition of Co-Crystallization of Olmesartan Medoxomil and Hydrochlorothiazide for Enhanced Dissolution Rate in Their Fixed Dose Combination. AAPS PharmSciTech. 2018 Dec 17;20(1):3.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C, 3 years (Powder)
• Clinical Information: No Development Reported